More than 1,000 Risperdal lawsuits have been consolidated in Pennsylvania, where one of the first trials is likely to take place. The majority of the Risperdal lawsuits allege that the drug caused gynecomastia, or male breast tissue growth, in men, adolescents, and boys who were prescribed the drug.
Developed to treat schizophrenia, Risperdal is often given to younger males to address behaviors related to attention deficit hyperactive disorder (ADHD). The drug is also given to children in foster care at an alarmingly disproportional rate, despite drug manufacturer Janssen Pharmaceuticals being fined $2.2 billion for marketing the drug for unapproved uses.
Riserpdal has been found to increase levels of a hormone known as prolactin for an indefinite period of time. Prolactin has subsequently been associated with breast tissue growth in males. The condition is considered irreversible without surgery. As many as 25% of gynecomastia cases are associated with medications such as Risperdal.